Catalog No.
DHJ41099
Description
Enfortumab vedotin-ejfv is an ADC consisting of a Nectin-4-directed antibody and Monomethyl auristatin E (MMAE) , suitable for adult patients with locally advanced or metastatic urothelial carcinoma, or who have received programmed cell death protein 1 (PD-1) inhibitor or programmed cell death ligand 1 (PD-L1) inhibitor therapy or neoadjuvant/adjuvant platinum-based chemotherapy for locally advanced or metastatic cancer.
Species reactivity
Human
Clonality
Monoclonal
Target
LNIR, NECTIN4, PRR4 receptor-related protein 4, Nectin cell adhesion molecule 4, Ig superfamily receptor LNIR, Nectin-4, PVRL4
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SEC.
Purification
Purified by Ion Exchange Chromatography.
Applications
Research Grade Biosimilar
Form
Liquid
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
Padcev, ASG-22ME
Clone ID
Enfortumab vedotin-ejfv
Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Erdafitinib vs Enfortumab Vedotin in Patients with Locally Advanced Metastatic Urothelial Carcinoma., PMID:39267886
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma., PMID:39230571
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma., PMID:38441576
A new era for bladder cancer: Enfortumab vedotin and pembrolizumab milestone approval., PMID:38142292
A potential platform of combining sialic acid derivative-modified paclitaxel cationic liposomes with antibody-drug conjugates inspires robust tumor-specific immunological memory in solid tumors., PMID:36825722
Overcoming Resistance to Anti-Nectin-4 Antibody-Drug Conjugate., PMID:35534238
Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma., PMID:35466857
A distinctive bullous skin reaction associated with enfortumab vedotin-ejfv treatment for metastatic urothelial cancer: A case report., PMID:34786831
Enfortumab Vedotin: Nursing Perspectives on the Management of Adverse Events in Patients With Locally Advanced or Metastatic Urothelial Carcinoma., PMID:33739346
FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma., PMID:32962979
Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma., PMID:32945172
The Evolution of Antibody-Drug Conjugates: A Positive Inflexion Point., PMID:32223669
Antibodies to watch in 2020., PMID:31847708
For research use only. Not for human or drug use.
